Background: Rectal signet ring cell carcinoma is a rare type of colorectal adenocarcinoma characterized by an aggressive biological behavior and poor prognosis. The co-occurrence of colorectal carcinoma and renal cell carcinoma (RCC) has found in many hundreds of patients, many of whom also have additional malignancies. Cancer to cancer metastasis is rare and an uncommon phenomenon in malignancy, especially at the time of initial diagnosis, suggesting a genetic susceptibility. Case presentation: We present the case of a 66-year-old Macedonian man with synchronous rectal signet ring cell carcinoma and RCC with tumor to tumor metastasis feature. He underwent a left nephrectomy and anterior rectal resection after complaining of constipation for 3–4 months and the appearance of synchronous tumors on the imaging studies. Morphology and immunohistochemical analysis of specimens from the RCC revealed signet ring cells identical to the rectal signet ring cell carcinoma. The next-generation sequencing study revealed mutations in TP53 and ERBB2, and microsatellite stable signet ring cell carcinoma was determined by deoxyribonucleic acid (DNA) sequencing. Conclusions: Cancer to cancer metastasis, although rare, needs to be considered in synchronous tumors. RCC, when diagnosed in multiple synchronous tumors, should be examined carefully. The paucity of reported cases indicates the need for advanced research in imaging methods for metastasis and new therapeutic approaches.
22 March 2018 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Accurate assessment of HER-2 is imperative in selecting patients for targeted therapy. Most commonly used test methods for HER-2 are immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). We evaluated the concordance between FISH and IHC for HER-2 in breast cancer samples using Food and Drug Administration approved tests.MATERIAL AND METHODS: Archived paraffin tissue blocks from 73 breast cancer patients were used. HER-2 immunostaining was performed using Ventana anti–HER-2 monoclonal antibody. The FISH assay was performed using PathVysion™ HER-2 DNA Probe Kit.RESULTS: Of the 73 cases 68.5% were IHC 0/1+, 15.07% were IHC 2+ and 16.44% were IHC 3+. Successful hybridisation was achieved in 72 cases. HER-2 FISH amplification was determined in 16.67% cases. Ten IHC 3+ and two IHC 2+ cases were FISH positive. Two of the IHC 3+ cases were FISH negative. Concordance rate was 100%, 18.18% and 83.33% for IHC 0/1+, 2+ and 3+ group, respectively. Total concordance was 84.72%, kappa 0.598 (p < 0.0001). The sensitivity of IHC in detecting IHC 2+ and IHC 3+ cases was 16.7% and 83.3%, and the specificity was 85% and 96.67%, respectively.CONCLUSION: The consistency between the methods was highest for IHC negative and lowest for IHC equivocal cases. The immunohistochemistry showed high sensitivity for IHC 2+/3+ cases and high specificity for IHC 3+ cases. Our results support the view that false-positive rather than false-negative IHC results are a problem with HER-2/IHC testing, and that IHC should be used as an initial screening test, but IHC 2+/ 3+ results should be confirmed by FISH.
Adenoid cystic/Basal-cell carcinoma (ACC/BCC) of the prostate is a rare histological type exhibiting various morphological characteristics and an optimal treatment has not yet been established. We report the case of a 63-year-old patient who complained of incomplete bladder emptying and recurrent urinary infection six months after transurethral resection of a high-grade urothelial bladder tumor. The clinical features, digital rectal examination, serum PSA levels, and multiparametric MRI did not refer to any suspicious prostatic lesions and cystoscopy revealed bladder neck hypertrophy, and yellowish zones in the prostatic urethra. Transurethral resection was performed due to these findings and histopathological analysis showed poorly differentiated ACC/BCC of the prostate. Even though there is no proven mutual correlation between ACC/BCC and urothelial bladder cancer, the appearance of obstructive urinary symptoms, bladder-neck hypertrophy, and macroscopic changes in prostatic urethra should be reconsidered for transurethral resection biopsy considering the possibility of ACC/BCC.
1 November 2025 in Journal of Surgical Case Reports
Amyand’s hernia, the presence of the vermiform appendix within an inguinal hernia sac, is a rare clinical entity (0.2%–1.7% of inguinal hernias). Acute appendicitis within the sac is rarer still, occurring in only 0.1% of cases. We describe a male patient presenting with an incarcerated right inguinal hernia, who developed diffuse peritonitis after manual reduction. Laparotomy revealed gangrenous perforated appendicitis with purulent peritonitis. Appendectomy, partial omentectomy, and peritoneal lavage were performed. The patient recovered uneventfully. Amyand’s hernia complicated by perforated appendicitis is an exceptional surgical emergency. Early recognition and prompt surgical management are crucial for favorable outcomes.
21 August 2026 in The Ukrainian Journal of Clinical Surgery
Objective. To determine the prevalence of antimicrobial resistance and the rate of empiric antibiotic coverage discordance in acute appendicitis under early preoperative antibiotic therapy.Materials and Methods. This prospective study included 50 adults undergoing appendectomy. All received preoperative ceftriaxone or ciprofloxacin. Luminal and mucosal cultures were obtained, and susceptibility testing was interpreted according to EUCAST 2026. ESBL production, carbapenem resistance, multidrug resistance (MDR), and empiric coverage discordance were evaluated.Results. ESBL-producing organisms were detected in 22% of patients and carbapenem-resistant organisms in 18%. MDR was present in 18%. Empiric coverage discordance occurred in 58% of patients and did not differ between complicated and uncomplicated appendicitis. No postoperative infectious complications were observed.Conclusion. Despite frequent microbiologic discordance, early surgical source control was not associated with postoperative infectious complications, underscoring the complex relationship between in vitro resistance and short-term outcomes.
Acute appendicitis is one of the most common causes of emergency abdominal surgery, yet clinicians continue to face difficulties in predicting disease severity, interpreting laboratory biomarkers, and explaining heterogeneous clinical presentations. Current classification systems primarily rely on severity-based progression models or etiology-based disease subtypes; however, both approaches incompletely explain the frequent discordance observed between pathological severity, systemic inflammatory response, microbiological findings, and clinical course. This conceptual limitation contributes to inconsistent biomarker performance and variability in study design across the appendicitis literature. In this conceptual review, we analyze the limitations of existing severity- and etiology-based frameworks and synthesize clinicopathological, microbiological, and biomarker evidence into an integrated multidimensional model of acute appendicitis. The proposed framework conceptualizes the disease along three interacting but partially independent axes: etiologic substrate, local pathological severity, and host systemic response. The etiologic substrate describes the initiating mechanism of appendiceal inflammation, local pathological severity reflects the extent of structural tissue injury, and host systemic response determines the magnitude of inflammatory amplification and biomarker expression. Recognizing host response as an independent modulating dimension provides a biologically plausible explanation for discordant biomarker findings and heterogeneous clinical trajectories. By reframing acute appendicitis as a multidimensional disease process rather than a binary entity or simple temporal continuum, this framework offers a coherent conceptual basis for improved interpretation of biomarkers, better study design, and more precise clinicopathological correlation. Adoption of such integrative models may ultimately support improved risk stratification and biologically informed management strategies in patients with acute appendicitis.